Robbins Umeda LLP Announces an Investigation of Cymer, Inc.
Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by members of the board of directors of Cymer, Inc. (NASDAQGS: CYMI) in connection with their efforts to sell the company to ASML Holding NV (NASDAQADR: ASML). Concerned shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly. You can also contact attorney Gregory E. Del Gaizo at (800) 350-6003.
On October 17, 2012, Cymer and ASML announced that they had entered into a definitive merger agreement under which Cymer will be acquired by ASML. According to the terms of the deal, ASML will acquire Cymer through a cash-and-stock transaction with a total value of approximately $2.5 billion based on ASML’s closing stock price on October 16, 2012. Cymer shareholders will receive a fixed 1.1502 shares of ASML ordinary stock plus $20.00 in cash in exchange for each share of Cymer ordinary stock. Based on ASML’s closing stock price on October 16, 2012, the implied value of a Cymer share is $81.64. The acquisition has already been approved by the boards of directors of both companies. The transaction is expected to close in the first half of 2013.
Robbins Umeda LLP’s investigation focuses on whether the board of directors at Cymer is undertaking a fair process to obtain maximum value and adequately compensate its shareholders. On July 24, 2012, Cymer reported second quarter of 2012 results with diluted earnings per share of $0.30 which beat analyst estimates of $0.04 by 600%. The second quarter of 2012 results marked the seventh time in the previous eight quarters that Cymer had beat analyst earnings per share estimates and the sixth time in the last eight quarters that the company’s revenue exceed analyst expectations. Given these financial results, Robbins Umeda LLP is examining the board of directors’ decision to sell Cymer now rather than allow shareholders to continue to participate in the company’s continued success and future growth prospects.
Robbins Umeda LLP attorneys highlight that Cymer shareholders have the option to file a class action lawsuit against the company to secure the best possible price for the company’s shareholders and the disclosure of material information to shareholders so they can vote on the transaction in an informed manner.
Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.